The wait is over - the Canadian Hypertension Congress (CHC 2026) is back in person for 2026, and it's going to be the most exciting meeting in hypertension yet.

Hosted by Hypertension Canada, the CHC 2026 is the only national conference in Canada dedicated entirely to high blood pressure - bringing together 200+ researchers, clinicians, pharmacists, specialists, nurses, dietitians, trainees, and public health leaders for three days of discovery, connection, and real-world impact.

This year's program is built around one big idea: the landscape of hypertension care is changing fast -and this is where you stay ahead of it.

Whether you're deep in the research trenches or on the front lines of patient care, you'll leave with fresh insights, practical tools, and a renewed sense of what's possible.

And if you're a trainee or early-career professional, don't miss the Early Career Investigators Forum - a dedicated space to share your work, meet your mentors, and find your place in the hypertension community.

Join us in Toronto this November. Your patients will thank you.

Registration Fees

At the conclusion of this activity, participants will be able to:

1. Summarize current national guideline recommendations for the diagnosis, thresholds, and treatment targets of hypertension.
2. Compare pharmacological and procedural options for blood pressure and cardio-renal protection, including GLP-1 receptor agonists, SGLT2 inhibitors, and bariatric surgery, in patients with obesity, diabetes, or chronic kidney disease.
3. Identify diagnostic and management strategies for postural orthostatic tachycardia syndrome (POTS), primary aldosteronism, and other secondary causes of hypertension.
4. Apply age- and stage-specific approaches to hypertension management across the lifespan, including pediatric, pregnancy and postpartum, and elderly populations.
5. Evaluate emerging and next-generation therapeutic options for resistant hypertension, including renal denervation and novel pharmacologic agents such as aprocitentan and baxdrostat.
6. Incorporate lifestyle and behavioural interventions, including dietary sodium and potassium modification and behavioural counselling, into hypertension prevention and management plans.
7. Describe emerging basic science evidence linking inflammation, gut microbiome composition, and vascular dementia to hypertension pathophysiology.
8. Apply best practices in ambulatory and home blood pressure monitoring to improve diagnostic accuracy.
9. Critique original basic science and clinical research findings presented through oral and poster abstract sessions, and discuss their implications for practice and future research.